NervGen Pharma Corp.

Recent News

  • NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer

    Vancouver, British Columbia--(Newsfile Corp. - April 22, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce the appointment of Daniel Mikol, MD, PhD, as the Company's Chief Medical Officer, effective May 5th, 2021. Dr. Mikol, who currently holds the position of Executive Medical Director, Global Clinical Development at Amgen, will oversee NervGen's medical and clinical...

    2021-04-22 8:30 AM EDT
  • NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291

    Vancouver, British Columbia--(Newsfile Corp. - April 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, has received approval and guidance from the Bellberry Human Research Ethics Committee ("HREC") in Australia on the design of a Phase 1 clinical trial for NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor. "We are pleased that the HREC found...

    2021-04-14 8:30 AM EDT
  • NervGen Pharma Reports 2020 Year End Results

    Vancouver, British Columbia--(Newsfile Corp. - April 8, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020.Paul Brennan, NervGen's President & CEO, stated, "We made substantial progress in the development of our lead program, NVG-291, towards clinical trials during 2020. We were able to resubmit our Investigational New...

    2021-04-08 4:30 PM EDT
  • NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury

    Vancouver, British Columbia--(Newsfile Corp. - March 8, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the European Medicines Agency ("EMA") has granted Orphan Designation for the treatment of spinal cord injury ("SCI") to NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor. This new EMA designation provides NervGen with multiple incentives, including improved access...

    2021-03-08 8:30 AM EST
  • NervGen Pharma Provides Regulatory Update on Development Program For NVG-291

    Vancouver, British Columbia--(Newsfile Corp. - March 4, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today provided a regulatory program update for NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor being developed for the treatment of spinal cord injury, multiple sclerosis and Alzheimer's disease. "The U.S. Food and Drug Administration ("FDA") has provided feedback regarding...

    2021-03-04 8:30 AM EST
  • NervGen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program

    Vancouver, British Columbia--(Newsfile Corp. - January 27, 2021) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will add an Alzheimer's disease patient cohort to its Phase 1 clinical trial program for its lead product, NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor.NervGen remains on track to initiate its Phase 1 program for...

    2021-01-27 8:30 AM EST
  • NervGen Pharma Establishes Alzheimer's Disease Scientific Advisory Board

    Vancouver, British Columbia--(Newsfile Corp. - January 26, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer's Disease Scientific Advisory Board ("AD-SAB") with the appointment of four world-class scientists and clinical researchers in Alzheimer's disease: Jeffrey Cummings, MD, ScD; George Perry, PhD; Henrik Zetterberg, MD, PhD; and Bruce Lamb, PhD. The AD-SAB will...

    2021-01-26 8:30 AM EST
  • NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

    Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Paul Brennan, President & CEO, will conduct a corporate presentation at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Wednesday, January 6, 2021 at 3:00pm Eastern Time. Investors interested can pre-register for NervGen's corporate presentation at this LifeSci...

    2021-01-05 8:30 AM EST